Gabriel Capellá, director of IDIBELL
appointment of Dr. Gabriel Capellá as director of IDIBELL.
Gabriel Capellá, director of IDIBELL Read More »
December 2016
Researchers describe the causes of resistance of tumor cells to therapy with mTOR inhibitors
Researchers from the proCURE ICO-IDIBELL breast cancer research group have first described why tumors adapt to and resist therapy with mTOR inhibitors, a treatment used in advanced stages of this cancer. The results of this international study, published in the journal Oncogene, sets new steps towards a more personalized selection of cancer therapies. The mTOR
Researchers identify new suppressor effects of the NOX4 protein in liver cancer
Researchers of the TGF-beta and Cancer group of Bellvitge Biomedical Research Institute (IDIBELL), in collaboration with King’s College London, have unveiled the role of NADPH oxidase NOX4 as an inhibitor of the epithelial-amoeboid transition, a process that contributes to the migration and invasion of tumor cells. The study has just been published in the journal
Researchers identify new suppressor effects of the NOX4 protein in liver cancer Read More »
L’Hospitalet Christmas Concerts raise funds for IDIBELL
The City Council and the research center join forces to raise funds against intellectual disability 100 years Sinatra
L’Hospitalet Christmas Concerts raise funds for IDIBELL Read More »
CaixaImpulse funds an IDIBELL project on hospital-acquired infections
Removal of antibodies with glycoconjugates Valuation and commercialisation, pending challenges
CaixaImpulse funds an IDIBELL project on hospital-acquired infections Read More »
IDIBELL, a ”Company with Value”
On November 10th, the Bellvitge Biomedical Research Institute (IDIBELL) was awarded the “Company with Value” badge by Vàlua entities. This award rewards the collaboration and commitment of IDIBELL with this platform and with equal opportunities of all people. A “Company with Value” is a company committed to citizenship: a company that cares about the well-being
IDIBELL, a ”Company with Value” Read More »
The first analysis of Ewing’s sarcoma methyloma opens doors to new treatments
Researchers of the Sarcoma research group of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Òscar Martínez-Tirado, have first described the methylation profile of Ewing’s sarcoma (ES), a cancer of bone and soft tissues that mainly affects children and teenagers. Their analysis has unveiled the potential of the PTRF gene as a prognostic marker
The first analysis of Ewing’s sarcoma methyloma opens doors to new treatments Read More »